| scholarly article | Q13442814 |
| P50 | author | Benjamin A. Lipsky | Q37830281 |
| P2093 | author name string | Benjamin A Lipsky | |
| Kamal Itani | |||
| Carl Norden | |||
| Linezolid Diabetic Foot Infections Study Group | |||
| P2860 | cites work | Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study | Q31918107 |
| Epidemiology of methicillin-resistant Staphylococcus aureus | Q33537224 | ||
| A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. II: treatment | Q33788802 | ||
| Evidence-based antibiotic therapy of diabetic foot infections | Q33881703 | ||
| Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections | Q33981016 | ||
| Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy | Q40599992 | ||
| Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis | Q40769706 | ||
| Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance | Q41676876 | ||
| Predicting nonelective hospitalization: a model based on risk factors associated with diabetes mellitus | Q42082802 | ||
| Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections | Q43811501 | ||
| Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections | Q43996924 | ||
| Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement | Q44049240 | ||
| Linezolid penetration into osteo-articular tissues | Q44198710 | ||
| Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem | Q44311731 | ||
| The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. | Q50629791 | ||
| Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. | Q50920358 | ||
| Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. | Q54076915 | ||
| Outpatient management of uncomplicated lower-extremity infections in diabetic patients | Q57543881 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| linezolid | Q411377 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 17-24 | |
| P577 | publication date | 2003-12-09 | |
| 2004-01-01 | |||
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate | |
| Treating Foot Infections in Diabetic Patients: A Randomized, Multicenter, Open‐Label Trial of Linezolid versus Ampicillin‐Sulbactam/Amoxicillin‐Clavulanate | |||
| P478 | volume | 38 |
| Q34420942 | A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes |
| Q35328383 | A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections |
| Q33363226 | A review of linezolid: the first oxazolidinone antibiotic |
| Q36009107 | A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. |
| Q37978286 | A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot |
| Q28242374 | Ampicillin/sulbactam: current status in severe bacterial infections |
| Q38070154 | An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy |
| Q36066093 | Antimicrobial interventions for the management of diabetic foot infections |
| Q37354361 | Antimicrobial therapy for bone and joint infections |
| Q43483925 | Are clindamycin and ciprofloxacin appropriate for the empirical treatment of diabetic foot infections? |
| Q33380788 | Benefit-risk assessment of linezolid for serious gram-positive bacterial infections |
| Q35146707 | Carbon nanotubes as in vivo bacterial probes |
| Q38270642 | Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience |
| Q36723810 | Clinical management of diabetic foot infection: diagnostics, therapeutics and the future |
| Q28394377 | Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections |
| Q37793714 | Complicated skin and soft tissue infection |
| Q35959551 | Complicated skin, skin structure and soft tissue infections - are we threatened by multi-resistant pathogens? |
| Q37809059 | Current medical management of diabetic foot infections |
| Q45230598 | Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections |
| Q79726889 | Diabetic foot disorders. A clinical practice guideline (2006 revision) |
| Q37924980 | Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus |
| Q36488312 | Diabetic foot infections: stepwise medical and surgical management |
| Q37149371 | Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. |
| Q36938282 | Diabetic foot ulcers--a comprehensive review. |
| Q34357233 | Diagnosis and treatment of diabetic foot infections |
| Q37988404 | Diagnostics and treatment of the diabetic foot |
| Q38257503 | Do diabetic foot infections with methicillin-resistant Staphylococcus aureus differ from those with other pathogens? |
| Q38197186 | EWMA document: Antimicrobials and non-healing wounds. Evidence, controversies and suggestions. |
| Q44561865 | Effect of daptomycin on local interleukin-6, matrix metalloproteinase-9, and metallopeptidase inhibitor 1 in patients with MRSA-infected diabetic foot |
| Q45752409 | Effect of daptomycin on local interleukin-6, matrix metalloproteinase-9, and metallopeptidase inhibitor 1 in patients with MRSA-infected diabetic foot |
| Q36592698 | Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study |
| Q44068744 | Efficacy and safety of neutral pH superoxidised solution in severe diabetic foot infections |
| Q33384409 | Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study |
| Q43044528 | Emergence of multi drug resistant bacteria in diabetic patients with lower limb wounds. |
| Q34468030 | Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. |
| Q40786989 | Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial |
| Q38439055 | Erythrocyte sedimentation rate and C-reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis |
| Q26828536 | Evidence-based management of PAD & the diabetic foot |
| Q37978287 | Expert opinion on the management of infections in the diabetic foot |
| Q38035802 | From ulcer to infection: an update on clinical practice and adjunctive treatments of diabetic foot ulcers |
| Q36409465 | Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. |
| Q38076744 | How long to treat with antibiotics following amputation in patients with diabetic foot infections? Are the 2012 IDSA DFI guidelines reasonable? |
| Q40991248 | IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes |
| Q38367413 | In diabetic foot infections antibiotics are to treat infection, not to heal wounds |
| Q36229278 | Infection in the neuroischemic foot |
| Q90354736 | Interventions in the management of infection in the foot in diabetes: a systematic review |
| Q38582118 | Interventions in the management of infection in the foot in diabetes: a systematic review |
| Q37463209 | Linezolid for patients with neutropenia: are bacteriostatic agents appropriate? |
| Q34894133 | Linezolid for the treatment of drug-resistant infections |
| Q56268956 | Linezolid for the treatment of skin and soft-tissue infections |
| Q33378032 | Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials |
| Q33368368 | Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections |
| Q37600404 | Linezolid: a review of safety and tolerability |
| Q36967288 | Linezolid: effectiveness and safety for approved and off-label indications |
| Q37642930 | MRSA and diabetic foot wounds: contaminating or infecting organisms? |
| Q84567210 | Maltodextrin-based imaging probes detect bacteria in vivo with high sensitivity and specificity |
| Q84446167 | Management of diabetic foot infections in an era of increasing microbial resistance |
| Q37654793 | Management of osteomyelitis of the foot in diabetes mellitus |
| Q85041190 | Medical Therapy of Diabetic Foot Infections |
| Q57543791 | Medical Treatment of Diabetic Foot Infections |
| Q35026548 | Methicillin-resistant Staphylococcus aureus in HIV-infected patients |
| Q37988851 | Neuropathic diabetic foot ulcers - evidence-to-practice |
| Q34768556 | New developments in diagnosing and treating diabetic foot infections |
| Q34878021 | New insights in diabetic foot infection |
| Q80170937 | Optimal management of uncomplicated skin and skin structure infections of the lower extremity |
| Q35922757 | Optimal treatment of infected diabetic foot ulcers |
| Q36729589 | Optimising antimicrobial therapy in diabetic foot infections |
| Q33205211 | Osteomyelitis |
| Q37858380 | Osteomyelitis: an update for hospitalists |
| Q35602940 | PET imaging of bacterial infections with fluorine-18-labeled maltohexaose. |
| Q46463152 | Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections |
| Q45258208 | Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis |
| Q36735202 | Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. |
| Q37642761 | Pharmacotherapy of diabetic foot osteomyelitis. |
| Q40058580 | Pitfalls in diagnosing diabetic foot infections |
| Q38217202 | Pristinamycin: old drug, new tricks? |
| Q36162348 | Role of linezolid in the treatment of orthopedic infections |
| Q46832064 | Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin |
| Q34478074 | Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. |
| Q36451493 | Systematic review of antimicrobial treatments for diabetic foot ulcers |
| Q28714211 | Systemic antibiotic therapy for chronic osteomyelitis in adults |
| Q24187313 | Systemic antibiotics for treating diabetic foot infections |
| Q64067856 | The History of Antibiotic Treatment of Osteomyelitis |
| Q64090135 | The Significant Association between Polymicrobial Diabetic Foot Infection and Its Severity and Outcomes |
| Q37954711 | The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms |
| Q34956122 | The interventional therapy for diabetic peripheral artery disease |
| Q36688351 | The neuropathic diabetic foot |
| Q35873712 | The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms |
| Q37458910 | The treatment of diabetic foot infections: focus on ertapenem |
| Q40757188 | The wound/burn guidelines - 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene |
| Q46260034 | Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream |
| Q57543731 | Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin–tazobactam/amoxicillin–clavulanate |
| Q36314096 | Treatment for diabetic foot ulcers |
| Q27015976 | Treatment of Gram-positive infections in critically ill patients |
| Q36758570 | Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions |
| Q81323178 | Treatment of community-associated methicillin-resistant Staphylococcus aureus |
| Q81756064 | Treatment of community-associated methicillin-resistant Staphylococcus aureus |
| Q35959558 | Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin |
| Q46977577 | Treatment of diabetic foot osteomyelitis: A surgical critique |
| Q37847723 | Treatment of skin and soft tissue infections in the elderly: A review |
| Q36283744 | Update on linezolid: the first oxazolidinone antibiotic |
| Q37116859 | Update on the appropriate use of linezolid in clinical practice |
| Q64117546 | Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience |
| Q34925381 | Zinc-triggered hydrogelation of self-assembled small molecules to inhibit bacterial growth |
Search more.